Figures & data
Table I. The chemical constituents of the two formulations used to microencapsulate BRIN BD11 pancreatic β- cells.
Figure 1. Micrographs of F1 and F2 microcapsules. a: Optical image of F1, b: SEM image of F1, c: Surface sites with corresponding EDXR spectral analysis of F1, d: Confocal images of stained cells of F1 microcapsules, e: Optical image of F2, f: SEM image of F2, g: Surface sites with corresponding EDXR spectral analysis of F2, h: Confocal images of stained cells of F2, and i: Confocal images of fluorescent UDCA images of F2 microcapsules. a and e: Scale 40 ±. d and h: Scale 10 3.
Figure 2. Microencapsulated β-cell viability within intact microcapsules without (control) and with (test) UDCA. Pre-MC: pre-microencapsulation β-cells, F1 (without UDCA) and F2 (with UDCA) are empty microcapsules, F1: β-cells microcapsules (without UDCA) and F2: β-cells microcapsules (with UDCA). Values are mean ± SD and n = 3.
Table II. Microencapsulated live cell count and the microencapsulation efficiencies for both formulations (F1 and F2).
Table III. Microcapsule size and Zeta potential of F1 and F2 formulations.
Figure 3. Swelling characteristics of β-cell-containing microencapsulated formulas F1 and F2 (a) and mechanical strength testing of β-cell-containing microcapsules F1 and F2.
